Summersalt Launches International Shipping
18.8.2021 14:01:00 EEST | Business Wire | Press release
Expanding Summersalt’s footprint globally, today the brand announces plans to introduce international shipping to over 180 countries in over 120 different currencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005211/en/
Summersalt’s 2021 “Everybody is a Summersalt Body” campaign (Photo: Business Wire)
Summersalt will launch globally with shipping to Canada, the United Kingdom, India, Australia, Africa, Asia, Europe, South America and more. International customers will be offered a localized check out experience based on their respective currency, language and payment preferences, as well as guaranteed customs, duties and shipping calculations.
“Launching internationally is a logical next step as we strategically build upon Summersalt’s growth domestically and as demand for the brand accelerates worldwide,” said Lori Coulter, CEO, President and Co-founder of Summersalt. “As a digitally native brand, we are excited to expand our reach into new markets and to offer a seamless online shopping and returns experience to Summersalt’s international community.”
“Our customer is a global citizen who loves to travel and explore, and has been requesting Summersalt via every channel since launch day. We are thrilled to offer Summersalt around the world,” said Reshma Chattaram Chamberlin, Chief Digital Brand Officer and Co-founder of Summersalt.
Summersalt was founded on a mission to bring back the childlike joy of wearing a swimsuit by offering designer-quality swimwear at an affordable price. Summersalt offers not only swimwear, but loungewear, activewear, sweaters, pajamas, intimates and more in sizes 0-24.
International expansion plans come on the heels of Summersalt’s highly celebrated “Everybody is a Summersalt Body” campaign, which featured 24 incredible and diverse women, and was centered around joy and self-expression, aiming to empower women to feel good about themselves.
About Summersalt
Summersalt is a generation-defining apparel brand, providing wardrobe essentials for women who are going places. Summersalt launched in 2017 with swimwear made from recycled materials at a $95 price point — designer quality swimwear without the designer price tag. Since then, we’ve launched additional categories including loungewear, knitwear, sleepwear, intimates and activewear. Summersalt pieces are modern, sophisticated and fun, with an impeccable data-backed fit based on millions of measurements from over 10,000 women. In the few short years since our founding, Summersalt has built a loyal following of customers, influencers and celebrities, while garnering praise from leading fashion media including Vogue, Harper’s Bazaar, ELLE and InStyle. In 2019, Summersalt was included in CNBC’s Upstart 100 list and also named one of Fast Company’s Most Innovative Companies in 2020.
To learn more about Summersalt, visit summersalt.com or follow the brand on Instagram and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005211/en/
Contact information
Amanda Jacobs
Email: summersalt@azionepr.com
Phone: 646-490-2945
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom